Cetuximab plus pemetrexed as second-line therapy for fluorouracil-based pre-treated metastatic esophageal squamous cell carcinoma
Cancer Chemotherapy and Pharmacology(2015)
摘要
Purpose The aim of this study was to evaluate the efficacy and toxicity of cetuximab and pemetrexed as the second-line treatment for advanced esophageal cancer patients, who had undergone treatment with the standard cisplatin and 5-FU regimens. Methods A total of 29 patients accepted this treatment. Cetuximab was administered at an initial dose of 400 mg/m 2 IV followed by weekly doses of 250 mg/m 2 IV, whereas pemetrexed 500 mg/m 2 was administered on day 1 every 3 weeks. Results Twelve patients (41.4 %) presented PR, ten (34.5 %) had SD, and seven (24.1 %) had PD. The response rate was 41.4 %. The median PFS was 4.5 months (95 % CI 4.1–4.9), and the median OS was 9.4 months (95 % CI 8.4–10.5). The expression levels of serum miR-335 were determined, and the subsequent analysis suggested that PFS was significantly different between the patients with higher level of serum miR-335 and those with low level of serum miR-335. The former had a PFS of 4.9 months (95 % CI 4.2–5.7) and the latter 4.1 months (95 % CI 3.7–4.5) (log rank = 0.025). None of the patients experienced grade 4 toxicity. Twenty-four patients presented rash. Conclusions A combination of cetuximab plus pemetrexed was marginally effective and well tolerated in patients with advanced esophageal squamous cell carcinoma as the second-line treatment.
更多查看译文
关键词
Advanced esophageal cancer,Cetuximab,Pemetrexed,Second-line therapy
AI 理解论文
溯源树
样例
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要